Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dengue fever vaccine (adenoviral vector)
- Development stage
- Preclinical
- Lead developer
- Asia Biotech Group
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous, Intradermal
01
Overview
This preclinical vaccine candidate, developed by Asia Biotech Group, utilizes an adenoviral vector platform to prevent dengue fever. The vaccine is engineered to express the Dengue virus coat protein E (envelope protein), which is the primary antigenic component responsible for viral attachment and entry into host cells. By delivering the genetic code for this protein via a non-replicating adenoviral vector, the vaccine aims to stimulate a comprehensive immune response, including the production of neutralizing antibodies and the activation of cellular immunity. This approach is intended to provide protection against infection by the dengue virus and is currently undergoing preclinical evaluation.
- Other names
- Asia Biotech Group dengue vaccineadenoviral vector dengue vaccine
02
Targets
E (Tick-borne encephalitis virus envelope protein)
Beyond the preview
Go deeper on dengue fever vaccine (adenoviral vector).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dengue fever vaccine (adenoviral vector).